Senior Director, Science Philanthropy Accelerator for Research and Collaboration (SPARC) team, Milken Institute Strategic Philanthropy
Sylvie Raver is a senior director on the Science Philanthropy Accelerator for Research and Collaboration (SPARC) team at Milken Institute Strategic Philanthropy. Raver applies her expertise in neuroscience, neurodegenerative disease, mental health, and biomedical research to identify opportunities for philanthropic investments that can have a transformative impact on medical research and health.
Managing Director, Science Philanthropy Accelerator for Research and Collaboration (SPARC) team, Milken Institute Strategic Philanthropy
Cara Altimus, PhD is a managing director on the Science Philanthropy Accelerator for Research and Collaboration (SPARC) team at Milken Institute Strategic Philanthropy, leading the science and health innovation portfolio. A PhD neuroscientist, Altimus advises individual philanthropists and foundations on the state of research for various areas including neurodegenerative disease and mental health, identifying opportunities where their capital can make the biggest impact.
Misophonia was named and described in the early 2000’s (Jastreboff and Jastreboff, 2001, 2002) and has since gained scientific recognition and clinical identification across a wide variety of disciplines (e.g., audiology, neuroscience, occupational therapy, psychiatry, and psychology). To the layperson, misophonia could be narrowly understood as a strong dislike of certain sounds, such as chewing. However, despite a common appreciation that misophonia is present in individuals when specific sensory input, such as a particular sound, leads to strong emotional and physical responses, researchers and clinicians have characterized the disorder differently (e.g., Jastreboff and Jastreboff, 2002; Edelstein et al., 2013; Schröder et al., 2013; Wu et al., 2014; Brout et al., 2018). Scientific research investigating misophonia has been conducted for fewer than 20 years and the literature on misophonia has only recently surpassed 100 peer-reviewed papers. During this early phase of research, misophonia has been defined by different criteria with variable methods used to diagnose and assess symptom severity. As a result of this fundamental lack of consensus regarding how misophonia is defined and evaluated, comparisons between study cohorts are not possible, measurement tools have not been well psychometrically validated, and the field cannot rigorously assess the efficacy of different treatment approaches.
The Misophonia Research Fund is pleased to release the 2023 Request for Proposals. The General Grant Program RFP is soliciting research proposals that aim to characterize misophonia, develop objective methods to assess misophonia, or...
While some sounds can be annoying for most people, for a few, certain sounds like chewing, sniffling, or pen clicking can trigger an intense physical and emotional response. Those with this condition can experience increased heart rate...
The Misophonia Research Fund (MRF) and the Milken Institute have partnered for the past four years to advance a world where misophonia is scientifically understood and effective treatments are available to help anyone who lives with this...
Washington D.C., (October 24, 2022) The Misophonia Research Fund today committed nearly $2.2 million in new grants to scientific investigators who seek to characterize misophonia and develop new therapeutic strategies for those living with...
Chad Clinton is the director of media relations for the Milken Institute. Hired to this role in August 2021, Clinton develops and executes strategies to amplify the Institute’s core messages by generating coverage of its pillar workstreams, experts, and events.
Situation Sarcoidosis is defined by the dramatic accumulation of granulomas—dense clusters of immune cells—in organs throughout the body. Individuals living with sarcoidosis often go undiagnosed for years, enduring symptoms such as...
Glioblastoma Multiforme (GBM) is an aggressive malignant brain tumor involving glial cells of the brain. At the time of this report, nearly 15,000 people were diagnosed with GBM each year in the United States and Europe. The prognosis for...
The Ann Theodore Foundation Breakthrough Sarcoidosis Initiative (ATF-BSI) is now accepting applications for two-year research projects that seek to increase our foundational understanding of sarcoidosis through projects focused on the...
The Ann Theodore Foundation and the Milken Institute are pleased to announce the five research teams selected to receive funding for research to advance understanding of the underlying biology of sarcoidosis, a poorly understood immune...
WASHINGTON, DC (September 20, 2023) — The Ann Theodore Foundation Breakthrough Sarcoidosis Initiative (ATF-BSI), in partnership with the Milken Institute, launched its latest round of funding today. Up to $3.4 million in total funding will...
Director, Communications, Milken Institute Strategic Philanthropy
Mala Persaud is the director of communications for Milken Institute Strategic Philanthropy. A former journalist, Persaud is a mission-driven communications leader with expertise in science and health communications.